With the recent FDA approval of SYFOVRE and more decisions and approvals expected in 2023, the Complement-Based Drug Development Summit is returning for its 7th year in a timely fashion. Be the first to view this year’s Event Guide below!
7th Complement-Based Drug Development Summit – 11-13 September, 2023
Reuniting experts across Nephrology, Neurology, Ophthalmology, and Haematology, join the leading companies showcasing the latest preclinical and clinical progress for complement-based therapeutics.
- With 30+ expert speakers from: AGTC, Alexion, Alnylam, Amgen, Annexon, Apellis – and that’s just the A’s!
- Covering more complement targets than ever before including C5aR2, Factor Bb and Combination Therapy, alongside an increased coverage of diseases
- Full of content for your whole team covering the most pressing challenges – from evaluating the value proposition of different fragments to target to designing clinical trials with high-risk patient populations
View the full list of sessions and expert speakers here.
This world-class speaker faculty will evaluate the entirety of the complement landscape, from scientific understanding to strategic, commercial intelligence. This means that no matter your role in the field, you’ll leave with tangible insights to further develop your complement pipeline.
